MAPT and Alzheimer disease: Future studies should incorporate the use of positron emission tomography (PET), cerebral spinal fluid (CSF) biomarkers of phosphorylated tau and Aβ in addition to clinical dementia rating (CDR) to exclude probable AD or diagnosed AD in the AF cohort.